紫杉醇、顺铂和替吉奥联合化疗方案治疗晚期胃癌的疗效和安全性分析  

Analysis of the Efficacy and Safety of Paclitaxel,Cisplatin and Tegafur Combined With Chemotherapy in the Treatment of Advanced Gastric Cancer

作　　者：张华[1] 金建华[1] 邓建忠[1] 陆文斌[1] 

机构地区：[1]江苏大学附属武进人民医院肿瘤内科,江苏常州210000

出　　处：《中国继续医学教育》2016年第25期161-163,共3页China Continuing Medical Education

摘　　要：目的探讨紫杉醇、顺铂和替吉奥治疗晚期胃癌的疗效。方法将我院晚期胃癌患者纳入研究,分为:研究组(治疗方案为替吉奥、紫杉醇、顺铂)和对照组(治疗方案为紫杉醇、顺铂)。对比(1)两组化疗2周期后治疗疗效。(2)两组毒副反应。结果 (1)两组化疗2周期后缓解率分别为56%、41%,两组比较,差异具有统计学意义(P<0.05)。(2)研究组和对照组毒副反应结果比较,差异无统计学意义(P>0.05)。结论紫杉醇、顺铂和替吉奥治疗晚期胃癌有较好的缓解率,安全性好。Objective To evaluate the clinical efficacy of paclitaxel, cisplatin and tegafur in the treatment of advanced gastric cancer.Methods In our hospital in patients with advanced gastric cancer were included in the study and was divided into： Research Group （treatment scheme for tegafur, paclitaxel, cisplatin） and control group （regimen in the treatment of paclitaxel and cisplatin）. Contrast （1） two groups after 2 cycles of chemotherapy treatment efifcacy. （2） toxicity and side effects of two groups. Results （1） the remission rates of the two groups after 2 cycles were 56% and 41%, respectively, and the difference was statistically significant （P〈0.05）. （2） there was no difference between study group and the control group in the toxicity （P〉0.05）.Conclusion Paclitaxel, cisplatin and tegafur for advanced gastric cancer have better remission rate, good safety.

关 键 词：胃癌 晚期 化疗 

分 类 号：R735.2[医药卫生—肿瘤]